Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient.

Claudia PestchankerMelina DiaconchukPaula LopezMaría Rosa MontañoWilliam RomeroGuillermo ZalazarEdgar Carnero Contentti

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)

Analytic control for satralizumab is recommended at 4 weeks. However, we recommend this control at week 2, in order to closely monitor neutrophil count and prevent further complications.

Keyphrases

spectrum disorder
chemotherapy induced
early onset
risk factors
clinical trial
randomized controlled trial
urinary tract infection
peripheral blood
preterm birth